AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Menkes Disease

Recent research efforts aimed at curing Menkes Disease.

Last updated

Menkes Disease

Overview

Menkes disease is a rare, X-linked genetic disorder caused by harmful variants in ATP7A, a gene needed to move copper from the intestine into the bloodstream and to distribute it to organs, especially the developing brain. It predominantly affects boys and can cause poor growth, seizures, low muscle tone, developmental delay, characteristic sparse or kinky hair, and problems affecting connective tissue, blood vessels, bones, bladder, and bowel. In the classical form, symptoms usually begin in infancy and children historically often died before age three. FDA approval announcement

The current disease-directed standard of care in the United States is early subcutaneous copper histidinate replacement, now marketed as Zycubo. On January 12, 2026, the FDA approved Zycubo as the first approved treatment for pediatric Menkes disease; it is given twice daily before age one and once daily from ages one through under 17, with blood copper, liver, kidney, electrolyte, and blood-count monitoring. Zycubo can improve survival but does not repair the underlying ATP7A gene, so it is not considered a cure. Zycubo prescribing information

Scope of Recent Research (2020–present)

Recent research has been active but concentrated in a small number of specialized groups. The dominant questions are how to deliver copper effectively into the brain early enough to prevent irreversible injury, whether ATP7A gene addition can restore copper handling throughout the body, and whether copper-carrying small molecules can bypass parts of the transport defect. The field has reached an important transition point—an approved copper-replacement therapy, strong combination-gene-therapy results in mice, and early human experience with elesclomol-copper—but no therapy has yet demonstrated a durable human genetic cure. NINDS URGenT project listing AAV9-ATP7A mouse study

Major Breakthroughs and Emerging Therapies

Copper replacement has become an approved disease-modifying treatment. In January 2026, the FDA approved copper histidinate, Zycubo, for children with Menkes disease after reviewing two open-label studies with external untreated controls. Among children with severe ATP7A variants who began treatment within four weeks of birth, the estimated risk of death was 78% lower than in untreated controls; 48% survived beyond six years and 23% beyond 12 years, whereas no external-control participant survived beyond six years. This is a major survival advance, particularly when treatment begins before neurological injury is established, but it remains replacement therapy rather than genetic correction. FDA Drug Trials Snapshot

AAV9 gene addition combined with copper histidinate is the leading potential curative strategy. In 2025, investigators used intravenous adeno-associated virus serotype 9 (AAV9) to deliver a codon-optimized, reduced-size working copy of ATP7A to newborn mottled-brindled mice, a severe Menkes model. When paired with early subcutaneous copper histidinate, the approach produced 95% long-term survival and improved brain and blood copper levels, growth, movement, and neurochemical measures. The reduced-size gene is necessary because the full ATP7A sequence exceeds AAV’s carrying capacity. These findings support a plausible one-time combination treatment, but they remain preclinical. AAV9-ATP7A mouse study

Copper ionophore therapy has moved from compelling mouse data to preliminary human evidence. Elesclomol is a small molecule that binds copper and can help shuttle it into cells and mitochondria, where copper-dependent enzymes are needed for energy production. In a 2020 Menkes mouse study, two injections of elesclomol-copper extended median survival from 14 to 203 days and improved brain copper delivery, neurodegeneration, and physical features. Elesclomol-copper mouse study In a 2025 report, two children treated under a Spanish exceptional-use protocol with weekly elesclomol-copper plus daily copper histidinate showed developmental gains or maintenance of largely normal development; injection-site inflammation and fat necrosis occurred, and connective-tissue manifestations persisted. The report is encouraging but is a two-patient uncontrolled case series, not proof of efficacy or cure. Elesclomol-copper in two children

Clinical Trials and Experimental Approaches

The clinical evidence supporting Zycubo came from NIH-led copper histidinate studies: a phase 1/2 study, NCT00001262, and a phase 3 study, NCT00811785. The FDA’s pooled primary efficacy analysis included 66 treated children and 17 untreated external controls; the full safety population included 129 treated children. Sentynl Therapeutics now markets the approved product, while the underlying studies established the evidence base for its approval. FDA Drug Trials Snapshot FDA approval announcement

A registered investigator-initiated study in China, NCT05507996, is evaluating recombinant AAV administration in children with molecularly confirmed Menkes syndrome. The single-center, open-label, single-arm study is sponsored by Kunming Hope of Health Hospital and lists survival or need for long-term ventilatory support, adverse events, development, growth, and head circumference as outcomes; the registry record does not report results. NCT05507996 trial record Separately, the FDA granted orphan-drug designation in July 2024 to Lantu Biopharma’s AAV9 vector carrying human ATP7A, but the designation does not mean the therapy is approved or clinically proven. FDA orphan-drug designation

Methodologies and Scientific Approaches

Researchers use the mottled-brindled mouse, which has a severe Atp7a defect and recapitulates key features of classical Menkes disease, to test survival, growth, movement, brain copper, blood copper, mitochondrial function, and brain neurochemistry after treatment. The leading gene-therapy platform uses AAV9, a viral delivery vehicle with the ability to reach nervous-system tissues, to supply a functional but compact ATP7A construct; copper histidinate is added because gene delivery alone may not rapidly correct copper deficiency in infancy. AAV9-ATP7A mouse study

Early diagnosis is itself a core cure-enabling technology because the therapeutic window is measured in weeks after birth. In 2026, investigators demonstrated whole-genome sequencing from newborn dried blood spots that detected all known ATP7A variants in a 24-subject test set, supporting a possible route to identify affected infants within the first four to six weeks of life, when treatment is most likely to protect neurological development. Whole-genome newborn-screening study

Leading Institutions and Funding

The principal U.S. translational effort is led by Stephen G. Kaler and collaborators at Nationwide Children’s Hospital and Columbia University, working with the NIH National Institute of Neurological Disorders and Stroke (NINDS) through its Ultra-rare Gene-based Therapy, or URGenT, Network. The program identifies the Menkes project as an AAV9/ATP7A viral-gene-therapy effort aimed at moving the combination approach toward a first-in-human study. NINDS URGenT project listing

In March 2024, NINDS awarded an approximately $4.1 million, three-year grant to the Research Institute at Nationwide Children’s Hospital and Dr. Kaler to complete preclinical safety, dose-selection, manufacturing, and investigational-new-drug preparation for AAV-ATP7A. Cyprium Therapeutics, a Fortress Biotech subsidiary, has supported development of the AAV-ATP7A program, while Sentynl Therapeutics developed and now markets copper histidinate as Zycubo. NINDS-supported AAV-ATP7A grant

Strengths, Limitations, and Challenges

The strongest recent evidence is that prompt copper replacement substantially improves survival, and the FDA approval creates a regulated, standardized treatment option rather than reliance on unapproved formulations. However, the pivotal evidence used open-label, single-arm studies with external controls rather than randomized concurrent controls—a practical design for an ultra-rare, life-threatening childhood disease, but one that limits certainty about the size of benefit and about effects in small demographic subgroups. Copper accumulation can also injure the kidneys, liver, and blood-forming system, requiring close monitoring. FDA Drug Trials Snapshot Zycubo prescribing information

Gene therapy addresses the disease mechanism more directly and has produced unusually strong results in mice, but it must still establish safe dosing, body-wide and brain-relevant delivery, durability, manufacturing consistency, and clinical benefit in infants. Elesclomol-copper may improve cellular copper delivery, yet the two-child report cannot separate treatment effect from individual variation or the effects of concurrent copper histidinate, and persistent connective-tissue disease shows that improvement in neurological development may not correct every ATP7A-dependent tissue defect. AAV9-ATP7A mouse study Elesclomol-copper in two children

Outlook and Future Directions

Menkes disease is not yet close to a proven human cure, but the outlook is substantially better than it was at the start of this decade. The key milestones to watch are initiation and results of a regulated first-in-human AAV9-ATP7A plus copper histidinate trial, publication of outcomes from the registered Chinese AAV study, larger controlled evaluation of elesclomol-copper, and implementation studies showing that genomic newborn screening can identify infants before symptoms emerge. A durable cure is most plausible if a treatment can restore enough ATP7A function early in life while supplying copper during the vulnerable newborn period. NINDS-supported AAV-ATP7A grant Whole-genome newborn-screening study

References

Don't see your disease? Request a report